Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. AbbVie (NYSE:ABBV) has agreed to acquire Capstan ...

In this video, we explain the capstan equation and how friction affects a rope or string wrapped around a surface. You’ll learn where the equation comes from, what each term means, and how it’s ...

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min AbbVie is about to acquire a ...

NEW YORK – AbbVie on Monday said it will acquire Capstan Therapeutics for up to $2.1 billion in cash to strengthen its immunology pipeline. San Diego-based Capstan develops cell therapies using ...

June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...

AbbVie wasn’t part of the first wave of cell therapies developed for cancer, but it is positioning itself to contend in the next one, which is expanding to therapies made by engineering immune cells ...

AbbVie (NYSE:ABBV) has agreed to acquire clinical-stage biotechnology company Capstan Therapeutics for up to $2.1 billion in cash. The transaction is subject to the satisfaction of customary closing ...